ReviewJournal of molecular biology2019
How Environmental Fungi Cause a Range of Clinical Outcomes in Susceptible Hosts.
Review in Journal of molecular biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Evolutionary trends in antifungal resistance: a meta-analysis.Microbiology spectrum · 2024Pooled it
- Mycotic infection as a risk factor for COVID-19: A meta-analysis.Frontiers in public health · 2022Pooled it
- Prevalence ofJournal of fungi (Basel, Switzerland) · 2026Article
- Molecular mechanisms drivingFrontiers in molecular biosciences · 2026Review
- Fungal infections in diabetic foot and other dermatoses: new species and clinical outcomes.Mycology · 2026Article
- From the Ground to the Clinic: The Evolution and Adaptation of Fungi.Journal of fungi (Basel, Switzerland) · 2025Review
- Biological Features, Antimicrobial Susceptibility and Phenotypic Characterization ofJournal of fungi (Basel, Switzerland) · 2025Article
- Effect of Aflasafe TZ01Toxins · 2025Article
- Urbanisation and Lockdown Impact on Airborne Fungal Communities in Tropical Landscapes: A Comparative Study of Urban and Peri-Urban Environments.Environmental microbiology reports · 2025Article
- Efficiency of the Coriolis µ Air Sampling Device for Fungal Contamination Analysis of Indoor Air: A Case Study.Pathogens (Basel, Switzerland) · 2025Article
- Occurrence of Pathogenic and Allergenic Molds in the Outdoor and Indoor Environment of a Major Hospital and Molecular Epidemiology ofJournal of fungi (Basel, Switzerland) · 2025Article
- Elements of dissemination in cryptococcosis.mBio · 2024Review
- Prevalence of fungal DNAemia mediated by putatively non-pathogenic fungi in immunocompromised patients with febrile neutropenia: a prospective cohort study.Journal of hematology & oncology · 2024Article
- Wake-up Call: Rapid Increase in Human Fungal Diseases under Climate Change.Environmental health perspectives · 2024Article
- Analysis of Mould Exposure of Immunosuppressed Patients at a German University Hospital.Microorganisms · 2023Article
- Increased Production of Pathogenic, Airborne Fungal Spores upon Exposure of a Soil Mycobiota to Chlorinated Aromatic Hydrocarbon Pollutants.Microbiology spectrum · 2023Article
- Identification of Pathogenic and Opportunistic Yeasts in Pigeon Excreta by MALDI-TOF Mass Spectrometry and Their Prevalence in Chon Buri Province, Thailand.International journal of environmental research and public health · 2023Article
- Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents.European journal of medicinal chemistry · 2023Review
- Considerations about the Geographic Distribution ofApplied and environmental microbiology · 2022Review
- Recent Advances in the Allergic Cross-Reactivity between Fungi and Foods.Journal of immunology research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Environmental fungi are globally ubiquitous and human exposure is near universal. However, relatively few fungal species are capable of infecting humans, and among fungi, few exposure events lead to severe systemic infections. Systemic infections have mortality rates of up to 90%, cost the US healthcare system $7.2 billion annually, and are typically associated with immunocompromised patients. Despite this reputation, exposure to environmental fungi results in a range of outcomes, from asymptomatic latent infections to severe systemic infection. Here we discuss different exposure outcomes for five major fungal pathogens: Aspergillus, Blastomyces, Coccidioides, Cryptococcus, and Histoplasma species. These fungi include a mold, a budding yeast, and thermal dimorphic fungi. All of these species must adapt to dramatically changing environments over the course of disease. These dynamic environments include the human lung, which is the first exposure site for these organisms. Fungi must defend themselves against host immune cells while germinating and growing, which risks further exposing microbe-associated molecular patterns to the host. We discuss immune evasion strategies during early infection, from disruption of host immune cells to major changes in fungal cell morphology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.